Evidence map›Paper›PMID 33204386›Full record

ArticleThe World Allergy Organization journal2020

World allergy organization anaphylaxis guidance 2020.

Victoria Cardona, Ignacio J Ansotegui, Motohiro Ebisawa, Yehia El-Gamal, Montserrat Fernandez Rivas, Stanley Fineman, Mario Geller, Alexei Gonzalez-Estrada, Paul A Greenberger, Mario Sanchez Borges and 6 more

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 468 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
468citing papers in PubMed, 6 pooled it
71.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07044180 phase4active not recruitingnot on this mapstarted 2025, after this paper: background citation

Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia: a Drug Safety Randomised Controlled Trial

TypeinterventionalSponsorTamas Vegh, MDRan2025 to 2028Enrolled80ConditionsNeuromuscular Blocking Agents, Residual Neuromuscular Block, Reversal of Neuromuscular BlockadeArmspipecuronium bromide, Rocuronium bromide
NCT07044193 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia: a Drug Safety Randomised Controlled Trial

TypeinterventionalSponsorTamas Vegh, MDRan2025 to 2028Enrolled80ConditionsNeuromuscular Blocking Agents, Residual Neuromuscular Block, Reversal of Neuromuscular BlockadeArmspipecuronium bromide, Rocuronium bromide
NCT07050134 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque

TypeinterventionalSponsorJunbo GeRan2025 to 2027Enrolled40ConditionsHypertriglyceridemia, Carotid Atherosclerotic PlaquesArmsDR10624 Injection;, DR10624 Injection Placebo (referred to as placebo)
NCT07231393 completednot on this map

Evaluation of Observation Periods and Biphasic Reaction Risk Factors in Pediatric Anaphylaxis Cases in the Pediatric Emergency Department: A Retrospective Study

TypeobservationalSponsorAydin Adnan Menderes UniversityRan2014 to 2025Enrolled67ConditionsChild, Anaphylaxis, Pediatric Emergency Care, Biphasic Anaphylactic Reaction
3 · Its place in the literature

Who cites it

468 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,034 citations in OpenAlex.

  1. Guideline
  2. 2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 11. First aid.Clinical and experimental emergency medicine · 2026
    Guideline
  3. Pooled it
  4. Guideline
  5. Tranexamic acid-induced anaphylaxis: a systematic review.European journal of clinical pharmacology · 2025
    Pooled it
  6. [Guideline for transfusion management in Chinese children with transfusion-dependent thalassemia (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Thermal stability and storage of adrenaline.The Cochrane database of systematic reviews · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. The Gap Between Prescription and Practice: Adrenaline Autoinjector Carriage in an Australian Cohort.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  17. Review
  18. Article
  19. A protocol proposal for safe dental anaesthesia in paediatric patients with allergic backgrounds: insights from a case series of allergic patients.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026
    Article
  20. Article

408 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 16 institutions in 13 countries.

Victoria CardonaAllergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, and ARADyAL research network, Barcelona, Spain.
Ignacio J AnsoteguiDepartment of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.
Motohiro EbisawaDepartment of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.
Yehia El-GamalPediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt.
Montserrat Fernandez RivasServicio de Alergia, Hospital Clınico San Carlos, IdISSC, Madrid, Spain.
Stanley FinemanDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Mario GellerDivision of Medicine, Academy of Medicine of Rio de Janeiro, Rio de Janeiro, Brazil.
Alexei Gonzalez-EstradaDivision of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Paul A GreenbergerDivision of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Mario Sanchez BorgesAllergy and Clinical Immunology Department, Centro Médico Docente La Trinidad and Clinica El Ávila, Caracas, Venezuela.
Gianenrico SennaAsthma Center and Allergy Unit, Verona University and General Hospital, Verona, Italy.
Aziz SheikhAllergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
Luciana Kase TannoHospital Sírio Libanês, Brazil andUniversity Hospital of Montpellier, São Paulo, Montpellier, and Sorbonne Université, INSERM Paris, France, and WHO Collaborating Centre on Scientific Classification Support Montpellier, and WHO ICD-11 Medical and Scientific Advisory Committee Geneva, Switzerland.
Bernard Y ThongDepartment of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.
Paul J TurnerNational Heart Lung Institute, Imperial College London and Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney, Australia.
Margitta WormDepartment of Dermatology and Allergology, Charite-Universitätsmedizin, Berlin, Germany.
Academia Nacional de Medicina · ARAin Shams University · EGCharité - Universitätsmedizin Berlin · DEEmory University · USHospital Clínico San Carlos · ESHospital Clínico Universitario de Caracas · VEHospital Quirónsalud Barcelona · ESHospital Regional Universitario de Málaga · ESInserm · FRJacksonville College · USNational Sagamihara Hospital · JPNorthwestern University · USTan Tock Seng Hospital · SGThe University of Sydney · AUUniversity of Edinburgh · GBUniversity of Verona · IT

Funding

Medical Research Council MR/K010468/1
6 · The paper itself

Abstract

Anaphylaxis is the most severe clinical presentation of acute systemic allergic reactions. The occurrence of anaphylaxis has increased in recent years, and subsequently, there is a need to continue disseminating knowledge on the diagnosis and management, so every healthcare professional is prepared to deal with such emergencies. The rationale of this updated position document is the need to keep guidance aligned with the current state of the art of knowledge in anaphylaxis management. The World Allergy Organization (WAO) anaphylaxis guidelines were published in 2011, and the current guidance adopts their major indications, incorporating some novel changes. Intramuscular epinephrine (adrenaline) continues to be the first-line treatment for anaphylaxis. Nevertheless, its use remains suboptimal. After an anaphylaxis occurrence, patients should be referred to a specialist to assess the potential cause and to be educated on prevention of recurrences and self-management. The limited availability of epinephrine auto-injectors remains a major problem in many countries, as well as their affordability for some patients.

Indexed as

ACE, Angiotensin converting enzymeAcute systemic allergic reactionAdrenalineAnaphylaxisAntihistaminesBAT, basophil activation testCAST, cellular allergen stimulation testCofactorsDrug allergyEAI, epinephrine auto-injectorsEpinephrineFcεRI, IgE high-affinity receptorFood allergyGlucocorticoidsGuidanceGuidelinesIgE, immunoglobulin EIgG, immunoglobulin GMRGPRX2, Mas-related G-protein coupled receptor member X2NSAIDs, nonsteroidal anti-inflammatory drugsVenom allergy

Identifiers

PMID33204386
PMCPMC7607509
OpenAlexW3097625054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.